/

KROS

Keros Therapeutics, Inc.Closed

11.23−0.38 −3.27%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 11.30 +0.62%

Open

11.69

Prev close

11.61

Day range

11.1911.69

52-week range

9.6922.55

Volume

143.61K0.75×

Mkt cap

222.66M

P/E ttm

—

Fwd P/E

-1.70

EPS ttm

-3.22

Div yield

0.00%

Earnings

Aug 3, 2026

From 52w high

−50.20%

Price Chart

Yahoo Finance · delayed

KROSOct 12, 2026O 11.77H 12.08L 11.58C 11.61−0.34 (−2.85%)Vol 223.70K

SMA 5011.10
SMA 20012.64

1Y change −26.05% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KROS Keros Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.78%
1 month: +4.78%
3 months: +4.59%
6 months: +4.13%
Year to date: −42.98%
1 year: −26.05%

Valuation & ownership

Market cap: 222.66M
Enterprise value: −19.22M
P/E (ttm): —
Forward P/E: -1.70
PEG ratio: —
Price / book: 0.85
Price / sales (ttm): 14.83
EV / EBITDA: 0.20
EPS (ttm): -3.22
EPS (forward): -6.62
Beta (5y monthly): 1.12
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 19.83M
Float: 17.77M
Short % of float: 6.67%
Short ratio (days): 6.41
Held by insiders: 3.96%
Held by institutions: 95.24%
Avg volume (3m): 192.61K
50-day average: 11.10
200-day average: 12.64
52-week change: −26.05%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 54.3
vs 50-day SMA: +4.57%
vs 200-day SMA: −8.14%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.53%
Realised vol (20d, ann.): 41.8%
From 52-week high: −48.51%
From 52-week low: +19.81%

ANR

Analyst Consensus

6 analysts

Consensus

Buy

1.86 on a 1 (strong buy) – 5 (sell) scale

Mean target

19.83

+76.61% implied

Low 16.00Median 19.00High 25.00

Recommendation trend

Now4 / 3 / 0
1m ago4 / 3 / 0

Buy / hold / sell counts

DES

About Keros Therapeutics, Inc.

Yahoo Finance profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 92
Headquarters: Lexington, MA, United States
Website: kerostx.com
Officers: Dr. Jasbir S. Seehra Ph.D. President, CEO & Director
Ms. Esther Cho J.D. Chief Legal Officer & Secretary
Ms. Annita Tanini

SEAS

Seasonality · KROS

2020–2026 · monthly returns

Strongest month Nov +14.89%Weakest month May −9.53%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-12.0	-20.8	-22.2	0.7	1.2	-4.9	-5.9	10.0	2.9	-1.5			−44.8%
2025	-28.0	-2.8	-8.0	41.7	-2.0	-5.7	7.3	6.2	4.0	-3.8	14.8	16.5	+28.6%
2024	39.2	21.9	-1.9	-14.8	-16.9	-2.5	9.8	-9.6	28.0	-0.1	-0.5	-72.6	−60.2%
2023	22.0	-9.1	-19.8	3.9	7.9	-16.0	4.2	-16.2	-9.2	-10.5	6.3	31.0	−17.2%
2022	-20.7	15.8	1.3	-2.5	-36.2	-18.3	16.1	10.3	6.4	33.8	-1.0	-3.7	−17.9%
2021	-19.1	14.8	-6.0	-4.5	-7.2	-22.2	-13.4	-8.6	17.6	5.5	33.7	4.9	−17.1%
2020					-2.7	30.5	-14.4	66.8	-28.0	44.2	36.0	-6.7	+138.7%

INSD

Insider Activity · KROS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

54.5K shares

Sells, 6 months

18.3K shares

Net shares

+36.2K

Net change in insider shares

+4.80%

Date	Insider	Transaction	Shares	Value
Aug 17, 2026	Newton Charles W.Director	Sale at price 10.30 per share.	551	$5.67K
Aug 17, 2026	Lerner Lorena Raquel Ph.D.Officer	Sale at price 10.29 per share.	3.6K	$36.72K
Aug 17, 2026	Cho EstherOfficer	Sale at price 10.29 per share.	4.5K	$46.15K
Aug 16, 2026	Bienaime Jean-JacquesDirector	Purchase at price 10.27 per share.	1K	$10.27K
Jul 14, 2026	Bienaime Jean-JacquesDirector	Purchase at price 10.61 per share.	1K	$10.61K
Jun 30, 2026	Prener AnneDirector	Stock Award(Grant) at price 0.00 per share.	13.8K	—
Jun 14, 2026	Bienaime Jean-JacquesDirector	Purchase at price 10.19 per share.	1K	$10.19K
Jun 10, 2026	Newton Charles W.Director	Sale at price 10.04 per share.	550	$5.52K
Jun 3, 2026	Seth AlpnaDirector	Sale at price 10.72 per share.	2.6K	$28.14K
Jun 3, 2026	Farzan NimaDirector	Sale at price 10.73 per share.	2.6K	$28.17K
Jun 3, 2026	Knowles JuliusDirector	Sale at price 10.73 per share.	2.6K	$28.17K
Jun 2, 2026	Bienaime Jean-JacquesDirector	Stock Award(Grant) at price 0.00 per share.	7.1K	—
Jun 2, 2026	Gray Mary AnnDirector	Stock Award(Grant) at price 0.00 per share.	7.1K	—
Jun 2, 2026	Seth AlpnaDirector	Stock Award(Grant) at price 0.00 per share.	7.1K	—
Jun 2, 2026	Farzan NimaDirector	Stock Award(Grant) at price 0.00 per share.	7.1K	—
Jun 2, 2026	Knowles JuliusDirector	Stock Award(Grant) at price 0.00 per share.	7.1K	—
May 14, 2026	Bienaime Jean-JacquesDirector	Purchase at price 10.58 per share.	1K	$10.58K
Apr 14, 2026	Bienaime Jean-JacquesDirector	Purchase at price 11.70 per share.	1K	$11.70K
Apr 1, 2026	Seehra JasbirChief Executive Officer	Conversion of Exercise of derivative security at price 0.30 per share.	55K	$16.50K
Mar 8, 2026	Newton Charles W.Director	Stock Award(Grant) at price 0.00 per share.	13.2K	—

13F

Investors Holding KROS

latest 13F filings of 29 followed managers

Investors holding KROS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$3.8M	0.01%	359.09K	−21%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

KROS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KROS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Keros Therapeutics, Inc.

Seasonality · KROS

Insider Activity · KROS

Congress Trades · KROS

Investors Holding KROS

Investors Holding KROS

Congress Trades · KROS

Insider Activity · KROS

Seasonality · KROS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Keros Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News